CVSI CV Sciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1510964 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.9%
TTM net income YoY-16.2%
TTM EPS YoY—
Revenue 3-yr CAGR-8.0%
Net income 3-yr CAGR—
Margins
Gross margin49.5%
Operating margin-2.5%
Net margin-13.7%
FCF margin-1.5%
EBITDA margin-1.8%
Returns
ROE-90.1%
ROA-25.6%
ROIC (approx.)-12.3%
Asset turnover1.86x
Leverage & solvency
Liabilities / assets64.7%
Debt / equity0.00x
Current ratio1.18x
Interest coverage-1.42x
Cash quality & payout
Operating cash flow / net income0.10x
Accruals ratio-23.0%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.03M | $2.98M | $3.19M | $3.31M | $3.26M | $3.62M | $3.61M | $3.88M |
| Cost of revenue | $1.51M | $1.53M | $1.63M | $1.64M | $1.68M | $1.78M | $1.95M | $2.21M |
| Gross profit | $1.51M | $1.45M | $1.56M | $1.67M | $1.58M | $1.84M | $1.66M | $1.68M |
| R&D expense | $19,000 | $18,000 | $18,000 | $18,000 | $24,000 | $50,000 | $30,000 | $25,000 |
| SG&A expense | $1.62M | $1.73M | $1.86M | $1.73M | $1.83M | $1.93M | $2.14M | $2.30M |
| Operating income | $377,000 | -$301,000 | -$318,000 | -$75,000 | -$275,000 | -$131,000 | $11,000 | -$646,000 |
| Interest expense | $0 | $1,000 | $93,000 | $129,000 | $107,000 | $130,000 | $151,000 | $94,000 |
| Pretax income | -$93,000 | -$770,000 | -$643,000 | -$204,000 | -$382,000 | -$261,000 | -$102,000 | -$740,000 |
| Income tax | $0 | $5,000 | $0 | $2,000 | $0 | $0 | $7,000 | -$14,000 |
| Net income | -$93,000 | -$775,000 | -$643,000 | -$206,000 | -$382,000 | -$261,000 | -$109,000 | -$726,000 |
| EBITDA | $400,000 | -$279,000 | -$295,000 | -$54,000 | -$244,000 | -$73,000 | $93,000 | -$532,000 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 226.10M | 205.09M | 186.92M | — | 184.26M | 184.26M | 184.26M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $308,000 | $266,000 | $309,000 | $278,000 | $381,000 | $886,000 | $812,000 | $454,000 |
| Receivables | $346,000 | $348,000 | $391,000 | $402,000 | $405,000 | $545,000 | $430,000 | $522,000 |
| Inventory | $3.96M | $3.96M | $3.90M | $4.09M | $4.08M | $4.22M | $4.37M | $4.90M |
| Current assets | $4.89M | $4.88M | $5.00M | $5.13M | $5.10M | $5.94M | $5.96M | $6.24M |
| PP&E, net | $302,000 | $319,000 | $329,000 | $344,000 | $349,000 | $363,000 | $364,000 | $399,000 |
| Goodwill | $990,000 | $999,000 | $1.00M | $1.01M | $1.01M | $1.01M | $988,000 | $971,000 |
| Intangibles | $55,000 | $62,000 | $68,000 | $76,000 | $82,000 | $88,000 | $90,000 | $93,000 |
| Total assets | $6.43M | $6.52M | $6.72M | $6.96M | $7.00M | $7.95M | $7.76M | $7.93M |
| Current liabilities | $4.15M | $4.94M | $5.18M | $5.00M | $4.79M | $5.71M | $5.25M | $6.11M |
| Short-term debt | $0 | $18,000 | $72,000 | $1.26M | $451,000 | $1.02M | $770,000 | $677,000 |
| Long-term debt | $0 | $0 | $0 | $387,000 | $504,000 | $208,000 | $498,000 | $0 |
| Total debt | $0 | $18,000 | $72,000 | $1.65M | $955,000 | $1.23M | $1.27M | $677,000 |
| Total liabilities | $4.16M | $4.95M | $5.22M | $5.49M | $5.46M | $6.15M | $5.87M | $6.13M |
| Shareholders' equity | $2.27M | $1.57M | $1.50M | $1.47M | $1.54M | $1.80M | $1.89M | $1.79M |
| Net debt | -$308,000 | -$248,000 | -$237,000 | $1.37M | $574,000 | $345,000 | $456,000 | $223,000 |
| Shares outstanding | 235.69M | 213.12M | 193.46M | 184.26M | 184.26M | 184.26M | 184.26M | 184.26M |
| Cash flow statement | ||||||||
| Operating cash flow | $63,000 | $20,000 | $101,000 | -$354,000 | -$259,000 | $287,000 | -$81,000 | -$164,000 |
| Capital expenditure | $0 | $7,000 | $3,000 | $9,000 | $11,000 | $49,000 | $40,000 | $18,000 |
| Free cash flow | $63,000 | $13,000 | $98,000 | -$363,000 | -$270,000 | $238,000 | -$121,000 | -$182,000 |
| Investing cash flow | $0 | -$7,000 | -$3,000 | -$9,000 | -$11,000 | -$49,000 | -$40,000 | -$22,000 |
| Financing cash flow | -$18,000 | -$54,000 | -$68,000 | $258,000 | -$234,000 | -$167,000 | $480,000 | -$335,000 |
| Depreciation & amortization | $23,000 | $22,000 | $23,000 | $21,000 | $31,000 | $58,000 | $82,000 | $114,000 |
| Stock-based compensation | $132,000 | $148,000 | $148,000 | $123,000 | $124,000 | $132,000 | $118,000 | $104,000 |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.